Molecular imaging in oncology by means of nuclear medicine: Fact or fiction?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 2, 2004, Pages 151-154

  Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 4,5 BIS(THIOACETAMIDO)PENTANOYL TC 99M; ARABINOSIDE I 123; BRU59 21; BRU59 21 TC 99M; DEOXYURIDINE BR 76; DEOXYURIDINE I 124; DEOXYURIDINE I 131; DIACETYLBIS(N 4 METHYLTHIOSEMICARBAZONE) CU 62; ETHYLENEDICYSTEINE ANNEXIN V TC 99M; FLUORODEOXYGLUCOSE F 18; FLUOROTHYMIDINE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METHYLTHYMIDINE C 11; N1 IMINO 4 MERCAPTOBUTYL ANNEXIN V TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TETROFOSMIN TC 99M; THYMIDINE C 11; UNCLASSIFIED DRUG; UPENAZIME; UPENAZIME TC 99M;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DEATH; DRUG HALF LIFE; EDITORIAL; HUMAN; HYPOXIA; IMAGE ANALYSIS; ISOTOPE LABELING; MULTIDRUG RESISTANCE; NUCLEAR MEDICINE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

APOPTOSIS; DRUG RESISTANCE, MULTIPLE; HUMANS; NEOPLASMS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0842269093     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1416-6     Document Type: Editorial

References (30)

1. Bristow RG, Hill RP. Molecular and cellular basis of radiotherapy. In: Tannock IF, Hill RP, eds. The basic science of oncology, 3rd edn. New York: McGraw-Hill; 1987:295-321.
2. Fornace A, Fuks Z, Weichselbaum RR, Milas L. Radiation therapy. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The molecular basis of cancer. Philadelphia: Saunders; 2001:423-454.
3. Mendelsohn ML. The growth fraction: a new concept applied to tumours. Science 1960; 132:1496-1503.
4. Slingerland JM, Tannock IF. Cell proliferation and cell death. In: Tannock IF, Hill RP, eds. The basic science of oncology, 3rd edn. New York: McGraw-Hill; 1987:134-165.
5. Smith TAD. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998; 19:97-105.
6. Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2000; 2:71-88.
7. Krohn KA. Evaluation of alternative approaches for imaging cellular growth. Q J Nucl Med 2001; 45:174-178.
8. Van de Wiele C, De Bondt P, Peeters M, Vermeersch H, Dierckx RA. Radiolabelled thymidines and deoxyuridines for measuring cellular proliferation in tumours, an update. Nucl Med Commun 2002; 23:925-931.
9. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-3323.
10. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334.
11. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003; 30:1407-1412.
12. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63:2681-2687.
13. White E. Life, death and the pursuit of apoptosis. Gene Dev 1996; 10:1-15.
14. Zhivotovsky B, Joseph B, Orrenius S. Tumor radiosensitivity and apoptosis. Exp Cell Res 1999; 248:10-17.
15. Kaufman SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-49.
16. Van de Wiele C, Vermeersch H, Loose D, Signore A, Dierckx RA. Radiolabelled annexin-V for monitoring treatment response in oncology. Cancer Biother Radiopharm, 2003:in press.
17. Van De Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol 2003; 21:3483-3487.
18. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998; 48:149-156.
19. Hockel M, Schlenger K, Hockel S, et al. Association between tumor hypoxia and malignant progression: the clinical evidence in cancer of the uterine cervix. In: Vaupel P, Kelleher DK, eds. Tumour hypoxia. Stuttgart: Wissenschafte Verlagsgesellschaft; 1999:65-74.
20. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-39.
21. Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003; 55:5-15.
22. Hoebers FJ, Janssen HL, Olmos AV, et al. Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. Eur J Nucl Med Mol Imaging 2002; 29:1206-1211.
23. Aaronson SA. Growth factors and cancer. Science 1991; 254:1146-1153.
24. Cross M, Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991; 64:271-280.
25. Stone DK. Receptors: structure and function. Am J Med 1998; 105:244-250.
26. Signore A, Annovazzi A, Chianelli M, et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001; 28:1555-1565.
27. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 1987; 84:265-269.
28. Goldie JH, Goldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44:3643-3653.
29. Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999; 26:283-293.
30. 99mTc tetrofosmin scintigraphy for predicting resistance to chemotherapy: a critical review of clinical data. Nucl Med Commun 2003; 24:945-950.